<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02727608</url>
  </required_header>
  <id_info>
    <org_study_id>ICC version 2</org_study_id>
    <secondary_id>2014-005421-12</secondary_id>
    <nct_id>NCT02727608</nct_id>
  </id_info>
  <brief_title>Complement Inhibitor Eculizumab in Clinical Islet Transplantation</brief_title>
  <acronym>ICC</acronym>
  <official_title>Induction With Complement Inhibitor Eculizumab in Clinical Islet Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Uppsala University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Uppsala University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a dual centre, single arm, exploratory study of the possibility to use eculizumab
      (Soliris) to prevent/reduce destruction of islets of Langerhans after portal infusion of the
      islets in patients with diabetics accepted for islet transplant.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a dual centre, single arm, exploratory study of the possibility to use eculizumab
      (Soliris) to prevent/reduce destruction of islets of Langerhans after portal infusion of the
      islets in patients with diabetics accepted for islet transplant. Ten patients from 2 centres
      (Uppsala University Hospital and Karolinska University Hospital in Stockholm) will be
      transplanted. The purpose of the study is to investigate if selective complement inhibition
      by eculizumab combined with standard anticoagulation during and after transplantation can
      further reduce the extent of early tissue loss after portal infusion of islets.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 15, 2016</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">May 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Increased survival of ICC´s transplanted as measured by peak c-peptide</measure>
    <time_frame>During and within two hours post infusion (day 0).</time_frame>
    <description>Determined by PET-scan of 2-deoxy-27fluoro-D-glucose (18F) (FDG)-labelled islets infused in the portal vein.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of eculizumab on instant blood mediated inflammatory reaction (IBMIR) as determined by complement activation.</measure>
    <time_frame>At the end of infusion and 1 and 2 h post start of infusion (day 0).</time_frame>
    <description>Extent of early tissue loss</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of islet-function and survival.</measure>
    <time_frame>14, 30 and 75 days post-transplant.</time_frame>
    <description>Evaluation of insulin-independency, the extent of reduction of baseline insulin requirement, continuous glucose monitoring system (CGMS) performance, HbA1c, number of hypoglycemic events per week.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse events (AEs) and serious adverse events (SAEs)</measure>
    <time_frame>From start of infusion until 75 days post-transplant.</time_frame>
    <description>Will be assigned Medical Drug Regulatory Activities (MedDRA) preferred terms and tabulated as incidence rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient and graft survival at 75 days post treatment.</measure>
    <time_frame>From start of infusion until 75 days post-transplant.</time_frame>
    <description>Graft survival is measured by measurable stimulated c-peptide (&gt;0,1 nmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estimated glomerular filtration rate (GFR) (Cystatin C)</measure>
    <time_frame>At day 75</time_frame>
    <description>Cystatin C value</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Portal vein thrombosis</measure>
    <time_frame>The day after infusion</time_frame>
    <description>Assessment by per protocol ultrasound</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding</measure>
    <time_frame>From infusion until 2 hours post start of infusion</time_frame>
    <description>will be assessed by hemoglobin and thrombocyte monitoring (important while portal vein catheter is in place and withdrawn (within first week).</description>
  </secondary_outcome>
  <other_outcome>
    <measure>The percentage of loss of radioactivity in the liver field.</measure>
    <time_frame>Within the first two hours after start of islet infusion.</time_frame>
    <description>When logistically feasible. Determined by positron emission tomography (PET)-scan of 2-deoxy-27fluoro-D-glucose ((18F) (FDG)-labelled islets infused in the portal vein as assessed during treatment (only possible at the Uppsala site).</description>
  </other_outcome>
  <other_outcome>
    <measure>Effect of eculizumab on IBMIR</measure>
    <time_frame>Post infusion</time_frame>
    <description>Determined by coagulation activation (TAT)</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Eculizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eculizumab</intervention_name>
    <description>Intravenous infusion (1200 mg) over 35 minutes. Consecutive infusions (900 mg) on Days 1, 7 and 14.</description>
    <arm_group_label>Eculizumab</arm_group_label>
    <other_name>Soliris</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients between 18 to 65 years of age

          -  Patients able to provide written informed consent

          -  Absent stimulated c-peptide (&lt; 0.1 nmol/L). This includes also previously
             islet-transplanted patients with no detectable c-peptide.

          -  Patients at fear of severe hypoglycemia

          -  Female patients of child bearing potential must have a negative pregnancy test
             (s-β-HCG) and must be practicing an effective, reliable medical accepted contraceptive
             regimen while on eculizumab treatment and to study end at 75 days.

          -  Patients vaccinated against Neisseria meningitides or patients accepting adequate
             antibiotic prophylaxis

        Exclusion Criteria:

          -  Body mass index &gt; 30 kg/m2

          -  Untreated proliferative diabetes retinopathy

          -  Recipient of any other concomitant organ transplantation - Glomerular filtration rate
             &lt; 50 mL/min before first islet transplantation

          -  Positive T-cell cross-matching by Complement Depending Cytotoxicity (CDC)

          -  Pregnancy or lactating

          -  Active ongoing infection, bacterial or viral

          -  Unresolved meningococcal disease

          -  Known bleeding disorder

          -  Known complement disorder

          -  Have received any other investigational drug within 30 days before inclusion

          -  History of drug or alcohol abuse within the last year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gunnar Tufveson, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Uppsala University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gunnar Tufveson, MD, PhD</last_name>
    <phone>+46 (0)18 611 31 16</phone>
    <email>gunnar.tufveson@akademiska.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Dept of Surgical Sciences, Section of Transplantation Surgery, University Hospital</name>
      <address>
        <city>Uppsala</city>
        <zip>752 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gunnar Tufveson, MD,Professor</last_name>
      <phone>+46(0)186113116</phone>
      <email>gunnar.tufveson@akademiska.se</email>
    </contact>
    <contact_backup>
      <last_name>Gordana Kozlovacki, MD, PhD</last_name>
      <phone>+46(0)186110000</phone>
      <email>gordana.kozlovacki@akademiska.se</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Ryan EA, Paty BW, Senior PA, Bigam D, Alfadhli E, Kneteman NM, Lakey JR, Shapiro AM. Five-year follow-up after clinical islet transplantation. Diabetes. 2005 Jul;54(7):2060-9.</citation>
    <PMID>15983207</PMID>
  </reference>
  <reference>
    <citation>Eich T, Eriksson O, Lundgren T; Nordic Network for Clinical Islet Transplantation. Visualization of early engraftment in clinical islet transplantation by positron-emission tomography. N Engl J Med. 2007 Jun 28;356(26):2754-5.</citation>
    <PMID>17596618</PMID>
  </reference>
  <reference>
    <citation>Eich T, Eriksson O, Sundin A, Estrada S, Brandhorst D, Brandhorst H, Langstrom B, Nilsson B, Korsgren O, Lundgren T. Positron emission tomography: a real-time tool to quantify early islet engraftment in a preclinical large animal model. Transplantation. 2007 Oct 15;84(7):893-8.</citation>
    <PMID>17984843</PMID>
  </reference>
  <reference>
    <citation>Moberg L, Johansson H, Lukinius A, Berne C, Foss A, Källen R, Østraat Ø, Salmela K, Tibell A, Tufveson G, Elgue G, Nilsson Ekdahl K, Korsgren O, Nilsson B. Production of tissue factor by pancreatic islet cells as a trigger of detrimental thrombotic reactions in clinical islet transplantation. Lancet. 2002 Dec 21-28;360(9350):2039-45.</citation>
    <PMID>12504401</PMID>
  </reference>
  <reference>
    <citation>Bennet W, Sundberg B, Groth CG, Brendel MD, Brandhorst D, Brandhorst H, Bretzel RG, Elgue G, Larsson R, Nilsson B, Korsgren O. Incompatibility between human blood and isolated islets of Langerhans: a finding with implications for clinical intraportal islet transplantation? Diabetes. 1999 Oct;48(10):1907-14.</citation>
    <PMID>10512353</PMID>
  </reference>
  <reference>
    <citation>Koh A, Senior P, Salam A, Kin T, Imes S, Dinyari P, Malcolm A, Toso C, Nilsson B, Korsgren O, Shapiro AM. Insulin-heparin infusions peritransplant substantially improve single-donor clinical islet transplant success. Transplantation. 2010 Feb 27;89(4):465-71. doi: 10.1097/TP.0b013e3181c478fd.</citation>
    <PMID>20177350</PMID>
  </reference>
  <reference>
    <citation>Eriksson O, Eich T, Sundin A, Tibell A, Tufveson G, Andersson H, Felldin M, Foss A, Kyllönen L, Langstrom B, Nilsson B, Korsgren O, Lundgren T. Positron emission tomography in clinical islet transplantation. Am J Transplant. 2009 Dec;9(12):2816-24. doi: 10.1111/j.1600-6143.2009.02844.x. Epub 2009 Oct 21.</citation>
    <PMID>19845588</PMID>
  </reference>
  <reference>
    <citation>Friberg AS, Brandhorst H, Buchwald P, Goto M, Ricordi C, Brandhorst D, Korsgren O. Quantification of the islet product: presentation of a standardized current good manufacturing practices compliant system with minimal variability. Transplantation. 2011 Mar 27;91(6):677-83. doi: 10.1097/TP.0b013e31820ae48e.</citation>
    <PMID>21248660</PMID>
  </reference>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 29, 2016</study_first_submitted>
  <study_first_submitted_qc>March 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 4, 2016</study_first_posted>
  <last_update_submitted>May 18, 2017</last_update_submitted>
  <last_update_submitted_qc>May 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Complement System Proteins</mesh_term>
    <mesh_term>Complement Inactivating Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

